Edy Firmina Pereira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Edy Firmina Pereira has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Ana Paula da Costa Marques
Universidade Federal de Mato Grosso do Sul, Brasil
1 shared publication - Anamaria Mello Miranda Paniago
Federal University of Mato Grosso do Sul, Brazil
1 shared publication - Lídia Raquel de Carvalho
São Paulo State University, Brazil
1 shared publication - Marilene Rodrigues Chang
Graduate Program in Infectious and Parasitic Diseases, Faculty of Medicine, Federal University of Mato Grosso do Sul, Campo Grande 79070-900, MS, Brazil
1 shared publication - Rinaldo Poncio Mendes
Federal University of Mato Grosso do Sul, Brazil; São Paulo State University, Brazil
1 shared publication - Sandra Maria Do Valle Leone de Oliveira
School of Medicine, Federal University of Mato Grosso do Sul , Campo Grande, Mato Grosso do Sul
1 shared publication
Latest Publications
- Open Access
- 1 January 2019
- Published by FapUNIFESP (SciELO) in Jornal Brasileiro de Pneumologia
- Vol. 45 (2) , e20180167
Treatment compliance of patients with paracoccidioidomycosis in Central-West Brazil
Objective: To evaluate the treatment compliance of patients with paracoccidioidomycosis. Methods: We studied 188 patients with paracoccidioidomycosis admitted to a tertiary referral hospital in the Central-West Region of Brazil from 2000 to 2010, to assess their compliance to treatment. In order to be considered compliant, patients needed to present two established criteria: (1) receive medicines from the pharmacy, and (2) achieve a self-reported utilization of at least 80% of the dispensed antifungal compounds prescribed since their previous appointment. Results: Most patients were male (95.7%), had the chronic form of the disease (94.2%), and were treated with cotrimoxazole (86.2%). Only 44.6% of patients were treatment compliant. The highest loss to follow-up was observed in the first 4 months of treatment (p < 0.02). Treatment compliance was higher for patients with than for those without pulmonary involvement (OR: 2.986; 95%CI 1.351-6.599), and higher for patients with than without tuberculosis as co-morbidity (OR: 2.763; 95%CI 1.004-7.604). Conclusions: Compliance to paracoccidioidomycosis treatment was low, and the period with the highest loss to follow-up corresponds to the first four months. Pulmonary paracoccidioidal involvement or tuberculosis comorbidity predicts a higher compliance to paracoccidioidomycosis therapy.
- 1 January 2019
- Published by FapUNIFESP (SciELO) in Jornal Brasileiro de Pneumologia
- Vol. 45 (2) , e20180167
Open AccessTreatment compliance of patients with paracoccidioidomycosis in Central-West Brazil
Objective: To evaluate the treatment compliance of patients with paracoccidioidomycosis. Methods: We studied 188 patients with paracoccidioidomycosis admitted to a tertiary referral hospital in the Central-West Region of Brazil from 2000 to 2010, to assess their compliance to treatment. In order to be considered compliant, patients needed to present two established criteria: (1) receive medicines from the pharmacy, and (2) achieve a self-reported utilization of at least 80% of the dispensed antifungal compounds prescribed since their previous appointment. Results: Most patients were male (95.7%), had the chronic form of the disease (94.2%), and were treated with cotrimoxazole (86.2%). Only 44.6% of patients were treatment compliant. The highest loss to follow-up was observed in the first 4 months of treatment (p < 0.02). Treatment compliance was higher for patients with than for those without pulmonary involvement (OR: 2.986; 95%CI 1.351-6.599), and higher for patients with than without tuberculosis as co-morbidity (OR: 2.763; 95%CI 1.004-7.604). Conclusions: Compliance to paracoccidioidomycosis treatment was low, and the period with the highest loss to follow-up corresponds to the first four months. Pulmonary paracoccidioidal involvement or tuberculosis comorbidity predicts a higher compliance to paracoccidioidomycosis therapy.